Financial Performance - The company's operating revenue for Q1 2024 was approximately RMB 645.99 million, representing a year-on-year increase of 5.68%[3] - Net profit attributable to shareholders for the same period was approximately RMB 97.54 million, reflecting a growth of 20.16% compared to the previous year[3] - The basic earnings per share for Q1 2024 was RMB 0.58, which is an increase of 23.40% year-on-year[3] - Net profit for Q1 2024 was RMB 92,488,777.12, up 9.0% from RMB 84,951,683.69 in Q1 2023[18] - Operating profit for Q1 2024 was RMB 114,427,839.61, slightly up from RMB 111,265,909.95 in Q1 2023[17] Research and Development - Research and development expenses totaled approximately RMB 64.90 million, accounting for 10.05% of operating revenue, which is an increase of 1.28 percentage points from the previous year[3] - Research and development expenses increased to RMB 64,900,123.30 in Q1 2024, representing a 21.1% rise from RMB 53,624,174.05 in Q1 2023[17] Cash Flow - The net cash flow from operating activities was approximately RMB 75.97 million, which decreased by 4.96% year-on-year[3] - Cash flow from operating activities for Q1 2024 was RMB 75,969,702.64, compared to RMB 79,930,962.49 in Q1 2023[21] - Cash flow from investing activities showed a net inflow of RMB 1,140,250,242.38 in Q1 2024, significantly higher than RMB 335,310,779.40 in Q1 2023[20] - Cash flow from financing activities resulted in a net inflow of RMB 42,137,675.19 in Q1 2024, compared to a net outflow of RMB 20,935,703.98 in Q1 2023[23] Assets and Liabilities - The total assets at the end of the reporting period were approximately RMB 7.19 billion, showing a slight increase of 1.23% from the end of the previous year[3] - The total assets as of March 31, 2024, amounted to CNY 7,192,952,822.94, an increase from CNY 7,105,496,951.15 as of December 31, 2023[12][16] - Current assets totaled CNY 3,745,333,949.09, slightly down from CNY 3,750,143,782.75 in the previous period[12] - Non-current assets increased to CNY 3,447,618,873.85 from CNY 3,355,353,168.40, indicating growth in long-term investments[13] - Total liabilities decreased to CNY 1,070,720,682.01 from CNY 1,088,203,977.97, reflecting improved financial stability[15] - The company's equity increased to CNY 6,122,232,140.93 from CNY 6,017,292,973.18, showing a positive trend in shareholder value[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,438[7] - The top shareholder, Jiang Wei, holds 28.17% of the shares, amounting to 47,520,000 shares[8] - The number of shares held by the top ten unrestricted shareholders reflects significant ownership concentration, with Jiang Wei holding 47,520,000 shares[10] Inventory and Receivables - Accounts receivable slightly increased to CNY 328,757,543.44 from CNY 327,861,290.31, suggesting stable revenue collection[12] - Inventory levels rose to CNY 533,642,335.66 from CNY 526,173,607.73, which may indicate preparation for increased sales[12] Other Financial Metrics - The company reported a decrease in other comprehensive income, with a net amount of RMB -21,216,593.79 in Q1 2024 compared to RMB 3,063,929.44 in Q1 2023[18] - Cash and cash equivalents were reported at CNY 2,677,447,776.76, down from CNY 2,740,678,648.51, indicating a reduction in liquidity[12]
昊海生物科技(06826) - 2024 Q1 - 季度业绩